

REMARKS

Claims 1-106 are currently pending. Claims 8, 12 and 15-16 have been amended as explained below. Applicant respectfully requests reconsideration, a withdrawal of all rejections and a Notice of Allowability.

Applicants acknowledge the allowance of Claims 1-7, 9-15 and 22-106.

Claims 8 and 16-21 are rejected under 35 U.S.C. § 112, second paragraph, for indefiniteness. The Office states that Claims 8 and 16-18 lack proper antecedent basis. Applicants believe that the current amendments to Claims 8 and 15-16 address these issues, and respectfully request a withdrawal of this rejection.

Claim 12 has been amended to correct a minor typographical error.

It is submitted that all pending claims are in condition for allowance, action of which is respectfully requested. If the Examiner has any remaining concerns, he is encouraged to contact Applicant's undersigned agent at (919) 483-9616.

Respectfully submitted,

Date: February 6, 2008

/Robert J. Smith/
Robert J. Smith
Reg. No. 40,820
Attorney for Applicants

GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive
PO Box 13398
Research Triangle Park, NC 27709-3398
Direct Phone (919)483-9616
Facsimile (919)483-7988